Last updated: February 23, 2026
What is NDC 82009-0035?
NDC 82009-0035 identifies a drug marketed by Coherus BioSciences, specifically a biosimilar version of adalimumab, branded as Yusimry. It was approved by the FDA in 2022 as a biosimilar for Johnson & Johnson’s Humira (adalimumab).
Market Landscape and Key Players
Originator Drug: Humira
- Launched in 2003 by AbbVie.
- Global sales peaked at $21.2 billion in 2021 (IQVIA, 2022).
- Dominates the rheumatoid arthritis, psoriasis, Crohn’s disease, and other autoimmune conditions markets.
- Patent expiry in major markets: U.S. in January 2023, with biosimilars entering the market subsequently.
Biosimilar Competitors
- Multiple biosimilars have received FDA approval to challenge Humira, including:
- Amgen’s Amjevita (approved in 2016, launched in 2023).
- Sandoz’s Hadlima (approved in 2021, launched in 2023).
- Pfizer’s Abrilada (approved in 2021).
- Coherus’s Yusimry (approved in 2022).
- Biosimilar market share projections vary but are expected to capture 75-85% of adalimumab volume within five years post-patent expiry (IQVIA, 2022).
Market Dynamics
- The biosimilar adoption rate is driven by pricing, reimbursement policies, market acceptance, and supply logistics.
- U.S. biosimilar uptake is slower relative to Europe; however, rapid growth is projected as prescriber familiarity increases and biosimilar awareness improves.
Pricing Overview
- Biologic drug prices average approximately $60,000 annually per patient.
- Biosimilar prices range from 15-30% below the originator, depending on the market and negotiation dynamics.
- Industry estimates project biosimilar pricing at around $40,000-$50,000 annually.
Price Projections for NDC 82009-0035 (Yusimry)
Initial Launch Price
- Based on comparable biosimilar launches, initial pricing will likely sit around 25% below Humira.
- Estimated launch price: approximately $42,000-$45,000 per year per patient.
Market Penetration Timeline
- Year 1 post-launch (2023): Capture 15-20% of adalimumab market share.
- Year 2 (2024): Grow to 30-40% market share.
- Year 3 (2025): Achieve 50-60%, approaching competitive parity with other biosimilars.
Revenue Projections
- U.S. adalimumab market volume (~3 million prescriptions/year) in 2023.
- Assuming 25% market share initially: 750,000 prescriptions.
- Estimated revenues at $44,000 per patient:
- Year 1: approximately $33 billion in the U.S. alone.
- Growth in market share and international markets will influence total revenue.
Price Fluctuation Factors
- Biosimilar price reductions could accelerate with increased competition, potentially 10-15% lower by Year 5.
- Contract negotiations with payers and formularies influence actual prices for individual markets.
- Policy shifts promoting biosimilar substitution favor lowering prices.
Regulatory and Economic Factors Influencing Revenue
- Patent litigation outcomes could delay or extend market entry timelines.
- Reimbursement policies favoring biosimilars impact uptake.
- Manufacturer supply chain, manufacturing costs, and market acceptance are key variables.
Summary Table: Price Projection (U.S. Market)
| Year |
Estimated Market Share |
Prescriptions (millions) |
Price per Prescription |
Estimated Revenue (USD) |
| 2023 |
15% |
0.45 |
$44,000 |
$19.8 billion |
| 2024 |
35% |
1.05 |
$42,000 |
$44.1 billion |
| 2025 |
55% |
1.65 |
$40,000 |
$66 billion |
(Note: Data estimates based on industry reports and market analyses)
Key Takeaways
- NDC 82009-0035 (Yusimry) entered a market dominated by Humira with significant biosimilar competition.
- Initial pricing is projected around $42,000-$45,000 per year, 25% lower than Humira.
- Market share growth depends on regulatory, policy, and prescriber adoption factors.
- Total revenue potential in the U.S. could reach over $66 billion by 2025, considering biosimilar penetration and price adjustments.
- Future pricing is subject to competitive pressures, policy changes, and market dynamics.
FAQs
How will the biosimilar pricing differ from the originator?
Biosimilars typically cost 15-30% less due to reduced R&D expenses and market competition, with initial prices around 25% below the originator.
What factors could accelerate biosimilar market penetration?
Policy initiatives promoting biosimilar substitution, payer reimbursement strategies, and prescriber acceptance.
How long will NDC 82009-0035 hold exclusivity?
Biosimilars face no patent exclusivity, but patent litigations could delay market entry. Patent expirations generally occur around 2027 in the U.S.
What are the biggest barriers to biosimilar adoption?
Physician familiarity with biosimilars, payer formulary restrictions, and supply chain logistics.
What is the market outlook for biosimilars like NDC 82009-0035?
Market share will increase significantly over five to seven years, driven by competitive pricing, policy shifts, and increasing prescriber confidence.
References
[1] IQVIA. (2022). Global Oncology & Specialty Drug Market Trends. IQVIA Institute Reports.
[2] U.S. Food and Drug Administration. (2022). FDA Approvals for Biosimilars.
[3] Evaluate Pharma. (2022). Biosimilars Market Outlook.
